In our past work, we have suggested that therapeutic approaches that concurrently target Aβ and tau pathological pathways are the ones with the highest translatability potential to effectively treat AD in patients (Wisniewski and Goñi, 2015; Wisniewski and Drummond, 2019). This evidence concerns the gene MAPT and Alzheimer disease.